Codiak BioSciences Inc. (CDAK): Price and Financial Metrics
GET POWR RATINGS... FREE!
CDAK POWR Grades
- Value is the dimension where CDAK ranks best; there it ranks ahead of 92.41% of US stocks.
- The strongest trend for CDAK is in Growth, which has been heading down over the past 109 days.
- CDAK ranks lowest in Momentum; there it ranks in the 4th percentile.
CDAK Stock Summary
- With a market capitalization of $16,573,332, CODIAK BIOSCIENCES INC has a greater market value than just 6.92% of US stocks.
- In terms of volatility of its share price, CDAK is more volatile than 97.36% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CDAK comes in at -126.42% -- higher than that of just 4.87% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CODIAK BIOSCIENCES INC are SGTX, VYGR, CRDF, FUSN, and BPMC.
- To check out CODIAK BIOSCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001659352.
CDAK Valuation Summary
- In comparison to the median Healthcare stock, CDAK's price/sales ratio is 63.16% lower, now standing at 0.7.
- CDAK's price/earnings ratio has moved up 1.1 over the prior 29 months.
Below are key valuation metrics over time for CDAK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CDAK | 2023-03-17 | 0.7 | 0.6 | -1.3 | -1.9 |
| CDAK | 2023-03-16 | 0.5 | 0.5 | -1.1 | -1.6 |
| CDAK | 2023-03-15 | 0.5 | 0.4 | -1.0 | -1.5 |
| CDAK | 2023-03-14 | 0.5 | 0.5 | -1.0 | -1.6 |
| CDAK | 2023-03-13 | 0.5 | 0.5 | -1.1 | -1.6 |
| CDAK | 2023-03-10 | 0.6 | 0.5 | -1.1 | -1.7 |
CDAK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDAK has a Quality Grade of C, ranking ahead of 25.31% of graded US stocks.
- CDAK's asset turnover comes in at 0.106 -- ranking 260th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CDAK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.106 | 1 | -0.803 |
CDAK Price Target
For more insight on analysts targets of CDAK, see our CDAK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.67 | Average Broker Recommendation | 1.25 (Strong Buy) |
CDAK Stock Price Chart Interactive Chart >
CDAK Price/Volume Stats
| Current price | $0.44 | 52-week high | $7.15 |
| Prev. close | $0.46 | 52-week low | $0.30 |
| Day low | $0.42 | Volume | 61,600 |
| Day high | $0.46 | Avg. volume | 161,153 |
| 50-day MA | $0.60 | Dividend yield | N/A |
| 200-day MA | $1.31 | Market Cap | 16.21M |
Codiak BioSciences Inc. (CDAK) Company Bio
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.
Latest CDAK News From Around the Web
Below are the latest news stories about CODIAK BIOSCIENCES INC that investors may wish to consider to help them evaluate CDAK as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning! |
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx ConferenceCAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak’s Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Co |
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with a |
Codiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagCodiak BioSciences ( NASDAQ:CDAK ) Third Quarter 2022 Results Key Financial Results Revenue: US$522.0k (down 55% from... |
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue EstimatesCodiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
CDAK Price Returns
| 1-mo | -9.69% |
| 3-mo | N/A |
| 6-mo | -43.96% |
| 1-year | -92.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 10.66% |
| 2022 | -96.43% |
| 2021 | -65.51% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...